STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated with nivolumab in the CheckMate-057 phase III trial (0% vs. 57.1% vs. 18.2%; P = 0.047). In the SU2C cohort, KL LUAC exhibited shorter progression-free (P < 0.001) and overall (P = 0.0015) survival compared with KRASMUT;STK11/LKB1WT LUAC. Among 924 LUACs, STK11/LKB1 alterations were the only marker significantly associated with PD-L1 negativity in TMBIntermediate/High LUAC. The impact of STK11/LKB1 alterations on clinical outcomes with PD-1/PD-L1 inhibitors extended to PD-L1–positive non–small cell lung cancer. In Kras-mutant murine LUAC models, Stk11/Lkb1 loss promoted PD-1/PD-L1 inhibitor resistance, suggesting a causal role. Our results identify STK11/LKB1 alterations as a major driver of primary resistance to PD-1 blockade in KRAS-mutant LUAC. Significance: This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets. Cancer Discov; 8(7); 822–35. ©2018 AACR. See related commentary by Etxeberria et al., p. 794. This article is highlighted in the In This Issue feature, p. 781
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In NSCLC, alterations in STK11, KEAP1, and TP53 define biologically distinct molecular subsets with different immune phenotypes and treatment outcomes [75,76].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“However, co-mutations of other genes, especially STK11/LKB1 and KEAP1, were found to mediate resistance to anti-PD-1/PD-L1 therapy in KRAS-mutant NSCLC [156].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [156]
In the citing paper
“KRAS-mutant tumors with TP53 co-mutation often show higher inflammatory signaling and may be more responsive to immune checkpoint blockade.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 2×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 3×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 2×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Months KL KP K-only 54(0) 56(0) 64(0) 11(2) 26(3) 29(0) 5(3) 14(6) 20(3) 4(3) 9(10) 9(8) 2(4) 5(14) 3(13) 2(4) 1(15) 2(14) 1(4) 0(15) 2(14) 1(4) 0(15) 1(14) 0(4) 0(15) 0(15)”
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 4×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
InfluentialPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“11(0) 2(1) 0(3) 0(3) 0(3) 0(3) 0(3) 11(0)”
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Cited by
Items 301–400 of 1,004
Rossi, G., Russo, A., Tagliamento, M., Tuzi, A., Nigro, O., Vallome, G., Sini, C., Grassi, M., Bello, M. G. D., Coco, S., et al. (2020) · Cancers · doi:10.3390/cancers12051125 · Cited by 68
“, STK11, KEAP1) [67,68] or with improved outcomes with PD-1 plus CTLA-4 blockage (i.”
BackgroundResultLamberti, G., Sisi, M., Andrini, E., Palladini, A., Giunchi, F., Lollini, P., Ardizzoni, A., & Gelsomino, F. (2020) · Cancers · doi:10.3390/cancers12113129 · Cited by 70
“Mutation or loss of STK11 is associated with low or absent PD-L1 expression, in both KRAS-mutant and KRAS-wild type lung adenocarcinoma, and with impaired efficacy of ICIs targeting the PD-1/PD-L1 axis [16,54].”
BackgroundWu, X., Lv, D., Cai, C., Zhao, Z., Wang, M., Chen, W., & Liu, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.590618 · Cited by 74
Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1
Mortezaee, K., & Majidpoor, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114824 · Cited by 72
Ascierto, P. A., Bifulco, C. B., Palmieri, G., Peters, S., & Sidiropoulos, N. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.05.004 · Cited by 66
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease
Κhan, P., Siddiqui, J. A., Maurya, S. K., Lakshmanan, I., Jain, M., Ganti, A. K., Salgia, R., Batra, S. K., & Nasser, M. W. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.006 · Cited by 69
Frost, N., Kollmeier, J., Vollbrecht, C., Grah, C., Matthes, B., Pultermann, D., von Laffert, M., Lüders, H., Olive, E., Raspe, M., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-958 · Cited by 61
“In PD-L1 non-selected metastatic NSCLC, TP53mut consequently increased response to ICI and improved OS (HR, 0.48, 95% CI, 0.25–0.95, P=0.04) (36).”
BackgroundInfluentialMutational landscape and characteristics of ERBB2 in non‐small cell lung cancer
Wei, X., Gao, X., Zhang, X., Yang, J., Chen, Z., Wu, Y.-L. L. C., & Zhou, Q. H. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13419 · Cited by 68
Bergholz, J. S., Wang, Q., Kabraji, S. K., & Zhao, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2300 · Cited by 62
“adenocarcinoma identified genomic mutations on LKB1 as a significant biomarker for primary resistance to anti-PD-1/PD-L1 immunotherapy, as well as in another cohort of NSCLC irrespective of KRAS status (28).”
BackgroundKRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
Gu, M., Xu, T., & Chang, P. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211006950 · Cited by 70
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Désage, A.-L., Léonce, C., Swalduz, A., & Ortiz-Cuaran, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.796832 · Cited by 60
“KRAS/STK11 co-mutation might drive intrinsic resistance to PD1/PD-L1 inhibitors, as it was the only marker associated with PD-L1 negativity among 924 intermediate/high TMB lung adenocarcinoma patients (144).”
BackgroundAXL Inhibitors: Status of Clinical Development
Bhalla, S., & Gerber, D. E. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01392-7 · Cited by 67
Yang, X., Huang, C., Zhong, M., Zhong, H., Ruan, R., Xiong, J., Yao, Y., Zhou, J., & Deng, J. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02033-1 · Cited by 75
“The underlying mechanisms of resistance are complex and varied, mainly involving factors such as lack of tumor immune response, depletion and loss of T-cell function, and alterations in relevant genes [118–120].”
Opportunities and challenges of targeting cGAS–STING in cancer
Lu, C., Wang, W., & Fu, Y. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-025-00894-9 · Cited by 79
Hofman, P. M. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.85 · Cited by 64
“As an example, a mutation in STK11 associated to mutation in KRAS seems to be a robust biomarker to predict resistance to immunotherapy (15).”
BackgroundRetinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer
Bhateja, P., Chiu, M., Wildey, G. M., Lipka, M. B., Fu, P., Yang, M., Ardeshir‐Larijani, F., Sharma, N., & Dowlati, A. (2019) · Cancer Medicine · doi:10.1002/cam4.2023 · Cited by 72
Self-citationSun, D., Lu, T., Zhu, Y., Wo, Y., Liu, Q., Liu, S., Li, H., & Hou, H. (2020) · Molecular Medicine · doi:10.1186/s10020-020-00208-9 · Cited by 60
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
Rebuzzi, S. E., Zullo, L., Rossi, G., Grassi, M., Murianni, V., Tagliamento, M., Prelaj, A., Coco, S., Longo, L., Bello, M. G. D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052625 · Cited by 68
“However, co-occurring serine/threonine kinase (STK11) and KRAS mutations seem to be associated with PD-1 inhibitor resistance [80].”
BackgroundBai, X., Wu, D., Ma, S.-C., Wang, J., Tang, X.-R., Kang, S., Fu, Q. J., Cao, C., Luo, H.-S., Chen, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000381 · Cited by 67
Self-citationPalmero, R., Taus, Á., Viteri, S., Majem, M., Carcereny, E., Garde, J., Felip, E., Nadal, E., Malfettone, A., Sampayo-Cordero, M., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00241 · Cited by 65
“Knowledge of the tumor’s genomic status can also predict poor efficacy of ICPI therapy, as several studies have demonstrated reduced ORR in patients with EGFR, ALK, and STK11 (LKB1) mutations.(13,14) Finally, complete genomic testing and optimal first-line treatment selection are critical because only half of the pati…”
BackgroundChoudhury, N. J., Schoenfeld, A. J., Flynn, J. R., Falcon, C. J., Rizvi, H. A., Rudin, C. M., Kris, M. G., Arcila, M. E., Heller, G., Yu, H. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4650 · Cited by 67
Self-citationBashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 65
Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
Filipović, A., Miller, G., & Bolen, J. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00155 · Cited by 64
“Patients with metastatic, KRAS-mutated lung cancer, treated with at least one cycle of a PD-1 inhibitor or an anti-PD-1/PDL-1 and anti-CTLA-4 combination regimen, had STK11/LKB1 mutations largely drive the primary resistance to PD-1 blockade, in any regimen (Skoulidis et al., 2018).”
BackgroundMolecular predictors of response to pembrolizumab in thymic carcinoma
He, Y., Ramesh, A., Gusev, Y., Bhuvaneshwar, K., & Giaccone, G. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100392 · Cited by 67
Glasner, A., Rose, S. A., Sharma, R., Gudjonson, H., Chu, T., Green, J. A., Rampersaud, S., Valdez, I. K., Andretta, E. S., Dhillon, B. S., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01504-2 · Cited by 68
Self-citationSMARCA4 mutations in KRAS ‐mutant lung adenocarcinoma: a multi‐cohort analysis
Liu, L., Ahmed, T., Petty, W. J., Grant, S. C., Ruiz, J., Lycan, T. W., Topaloĝlu, Ü., Chou, P., Miller, L. D., Hawkins, G. A., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12831 · Cited by 59
“stratify KRAS-mutant LUAD patient into different subgroups with distinct biology, 17 therapeutic vulnerabilities and immune profiles [18], and immunotherapy response [19].”
BackgroundKocher, F., Amann, A., Zimmer, K., Geisler, S., Fuchs, D., Pichler, R., Wolf, D. G. F., Kurz, K., Seeber, A., & Pircher, A. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-380 · Cited by 65
Wang, Y., Cui, L., Georgiev, P., Singh, L., Zheng, Y., Yu, Y., Grein, J., Zhang, C., Muise, E. S., Sloman, D. L., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1896643 · Cited by 61
The Landscape of Immunotherapy Resistance in NSCLC
Frisone, D., Friedlaender, A., Addeo, A., & Tsantoulis, P. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.817548 · Cited by 65
“STK11 mutations in NSCLC may be associated with worse outcomes with ICIs since the inactivation of this serine threonine kinase involved in various cellular functions is associated with a low T lymphocytes tumor infi ltration and a “cold” tumor microenvironment (21, 22).”
BackgroundEmerging Therapeutic Implications of STK11 Mutation: Case Series
Laderian, B., Mundi, P. S., Fojo, T., & Bates, S. E. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0846 · Cited by 70
“Skoulidis et al. also retrospectively identified 66 patients with nonsquamous NSCLC who were treated with PD-1 or PD-L1 inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, or tremelimumab) and reported that STK11 mutations were associated with significantly lower overall response rate (p = .026) as well as…”
BackgroundInfluentialEvading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers
Corte, C. M. D., & Byers, L. A. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1286 · Cited by 69
“38(0) 61(0) 28(3) 29(5) 17(8) 12(14) 2(20) 5(19) 1(21) 3(20) 1(21) 2(21) 1(21) 2(21) 0(22) 1(22) 0(22) 0(23) 38(0) 61(0) 18(2) 14(3) 9(3) 7(4) 5(5) 5(4) 3(7) 3(5) 1(8) 2(5) 1(8) 1(5) 0(8) 0(5) 0(8) 0(5) Group mOS”
Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors
Bhatt, V. D., Lan, T., Wang, W., Kong, J., Lopes, E. C., Wang, J., Khayati, K., Raju, A., Rangel, M., Lopez, E., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05592-8 · Cited by 64
“Co-mutations of LKB1 or TP53 with KRAS define different subsets of NSCLC which exhibit different responses to standard cancer treatments [6, 9, 59].”
BackgroundSelf-citationPrognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 57
“Particularly, in patients with KRAS-mutant lung adenocarcinoma, STK11/LKB1 alterations are significantly associated with PD-L1 negativity and promote resistance to PD1 inhibitors (Skoulidis et al., 2018).”
BackgroundPD-L1 regulation revisited: impact on immunotherapeutic strategies
Lucibello, G., Mograbi, B., Milano, G. A., Hofman, P. M., & Brest, P. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.06.005 · Cited by 57
Hong, L., Aminu, M., Li, S., Lu, X., Petranović, M., Saad, M. B., Chen, P., Qin, K., Varghese, S., Rinsurongkawong, W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36328-z · Cited by 59
Self-citationCancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions
Watterson, A., & Coelho, M. A. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01063-x · Cited by 68
Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore
Li, R., Han, D., Shi, J., Han, Y., Tan, P., Zhang, R., & Li, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188420 · Cited by 67
Bravaccini, S., Bronte, G., & Ulivi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126536 · Cited by 64
“, STK11 mutations are associated with negative PD-L1 expression and high TMB [37], which is the opposite of the molecular profile found in one of our patients.”
Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities
Wang, H., Niu, X., Jin, Z., Zhang, S., Fan, R., Xiao, H., & Hu, S. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03519-z · Cited by 94
“LUAD with STK11/LKB1 deletion demonstrates low PD-L1 expression, reduced T-cell infiltration, and neutrophil enrichment, leading to primary resistance to immuno-therapy [32].”
Williams, E. A., Werth, A. J., Sharaf, R., Montesion, M., Sokol, E. S., Pavlick, D. C., McLaughlin-Drubin, M., Erlich, R., Toma, H., Williams, K. J., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00406 · Cited by 58
“STK11 has been previously correlated with poor response to anti–programmed death-1 therapy in KRAS-mutant lung adenocarcinoma.(35) It is conceivable that a similar role could exist in HPV+ vSCC as a putative tumor immuneescape mechanism, but additional studies are needed.”
BackgroundSelf-citationLi, A., Wang, Y., Yu, Z., Tan, Z., He, L., Fu, S., Shi, M., Du, W., Luo, L., Li, Z., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.07.020 · Cited by 62
WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses
Mortezaee, K. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01274-z · Cited by 65
“Silencing intracellular LKB1 is also followed by an increase in the level of PD-L1 [77], and the loss of Stk 11/ Lkb 1 is reported to promote resistance to anti-PD-(L)1 in KRAS mutant lung adenocarcinoma [78] (Fig.”
BackgroundKRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma
Budczies, J., Romanovsky, E., Kirchner, M., Neumann, O., Blasi, M., Schnorbach, J., Shah, R., Bozorgmehr, F., Savai, R., Stiewe, T., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02746-z · Cited by 74
“In a recent study of KRAS-mutated lung adenocarcinoma, objective response rates to ICI differed among tumours with STK11/LKB1 co-mutation, tumours with TP53 co-mutation, and tumours without such co-mutations [11].”
BackgroundRemón, J., Lacroix, L., Jovelet, C., Caramella, C., Howarth, K., Plagnol, V., Rosenfeld, N., Morris, C. D., Mezquita, L., Pannet, C., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00211 · Cited by 55
“In our cohort, 44% of patients without tissue biopsy had ctDNAdetected clinically relevant mutations for personalized treatment as well as putative negative predictive markers of immunotherapy efficacy, such as STK11mutation.14,26 Also, ctDNA testing demonstrated feasibility of use as complementary to tissue testing b…”
BackgroundThe Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Tunger, A., Sommer, U. J., Wehner, R., Kubasch, A. S., Grimm, M., Bachmann, M. P., Platzbecker, U., Bornhäuser, M., Baretton, G. B., & Schmitz, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101534 · Cited by 55
Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy
Lagos, G., Izar, B., & Rizvi, N. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_289967 · Cited by 61
Burns, T. F., Borghaei, H., Ramalingam, S. S., Mok, T. S. K., & Peters, S. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00744 · Cited by 65
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
Sivapiragasam, A., Kumar, P. A., Sokol, E. S., Albacker, L. A., Killian, J. K., Ramkissoon, S. H., Huang, R. S. P., Severson, E. A., Brown, C. A., Danziger, N. A., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3550 · Cited by 55
Self-citationPu, X., Wu, L., Su, D., Mao, W., & Fang, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4990-5 · Cited by 58
Nanomedicine in Lung Cancer Immunotherapy
Doroudian, M., Zanganeh, S., Abbasgholinejad, E., & Donnelly, S. C. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1144653 · Cited by 55
“This may be due to multiple factors, including the development of new mutations, alterations in the tumor microenvironment, and immune escape mechanisms (Pardoll, 2012; Dong et al., 2017; Skoulidis et al., 2018).”
BackgroundStein, M. K., Pandey, M. K., Xiu, J., Tae, H., Swensen, J. J., Mittal, S., Brenner, A. J., Korn, W. M., Heimberger, A. B., & Martin, M. G. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00376 · Cited by 59
Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)
Sherman, S., Rotem, O., Shochat, T., Zer, A., Moore, A., & Dudnik, E. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.008 · Cited by 63
Goldman, J. W., Mazieres, J., Barlesi, F., Dragnev, K. H., Koczywas, M., Göskel, T., Cortot, A. B., Girard, N., Wesseler, C., Bischoff, H., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.578756 · Cited by 52
“The KRAS+TP53 and KRAS-only tumors (lack TP53 or STK11 co-mutations) are more sensitive to PD-1/programmed deathligand 1 (PD-L1) inhibitors, while KRAS+STK11 are least sensitive (26).”
BackgroundReplication Stress Defines Distinct Molecular Subtypes Across Cancers
Takahashi, N., Kim, S. H., Schultz, C. W., Rajapakse, V. N., Zhang, Y., Redon, C. E., Fu, H., Pongor, L. S., Kumar, S., Pommier, Y. G., et al. (2021) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0168 · Cited by 70
Anagnostou, V., Landon, B. V., Medina, J. E., Forde, P. M., & Velculescu, V. E. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3958 · Cited by 54
Cyclic fasting-mimicking diet in cancer treatment: Preclinical and clinical evidence
Vernieri, C., Ligorio, F., Tripathy, D., & Longo, V. D. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.06.014 · Cited by 60
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
Skoulidis, F., Li, B. T., Langen, A. J. D., Hong, D. S., Léna, H., Wolf, J., Dy, G. K., Fontecedro, A. C., Tomasini, P., Velcheti, V., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03732-5 · Cited by 68
“Co-occurring genomic alterations detected at baseline have been reported to affect responses to diverse systemic therapies, including KRAS(G12C) inhibitors 22,23 .”
Self-citationFederico, A. D., Stumpo, S., Mantuano, F., Giglio, A. D., Bianco, F. L., Pecci, F., Alessi, J. V., Wang, X., Sperandi, F., Melotti, B., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00429-2 · Cited by 68
Self-citationTargeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 80
“…to PD-1/PD-L1 and docetaxel in patients with STK11 mutations and KRAS - mutated NSCLC. 140,197,198 These fi ndings identi fi ed a subgroup with a potential response and suggested that STK11 -mutant/ KEAP1 -wild-type status is a biomarker for the response to sotorasib in KRAS G12C -mutant NSCLC 199 .”
Tuccitto, A., Shahaj, E., Vergani, E., Ferro, S., Huber, V., Rodolfo, M., Castelli, C., Rivoltini, L., & Vallacchi, V. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2477-z · Cited by 56
LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer
Bonanno, L., Zulato, E., Pavan, A., Attili, I., Pasello, G., Conte, P., & Indraccolo, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081874 · Cited by 57
“The potential predictive role of LKB1 impairment in causing resistance to ICIs treatment is supported by interesting preclinical evidence and, if further confirmed, may potentially change the therapeutic approaches to KL NSCLCs.”
BackgroundInfluentialImmunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments
Ngo, C., & Postel-Vinay, S. C. (2022) · Biomedicines · doi:10.3390/biomedicines10030650 · Cited by 57
“Several tumor-related factors have been shown to influence response to immune therapies, including the tumor mutational burden (TMB) and neoantigen load [60], or the mutation in genes that influence tumor ability to escape immune surveillance [56] (e.g., MYC or RAS [61,62]) or respond to interferon-gamma (IFNγ) signal…”
BackgroundLong-read sequencing for non-small-cell lung cancer genomes
Sakamoto, Y., Xu, L., Seki, M., Yokoyama, T., Kasahara, M., Kashima, Y., Ohashi, A., Shimada, Y., Motoi, N., Tsuchihara, K., et al. (2020) · Genome Research · doi:10.1101/gr.261941.120 · Cited by 59
“Recent studies have reported that immune checkpoint inhibitors are less effective for lung cancers with STK11 mutations (Rizvi et al. 2018; Skoulidis et al. 2018).”
BackgroundBiomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Park, S., Joung, J., Min, Y. W., Nam, J., Ryu, D., Oh, D., Park, W., Lee, S. K., Choi, Y., Ahn, J. S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0609-x · Cited by 57
Jin, Y., Bao, H., Le, X., Fan, X., Tang, M., Shi, X., Zhao, J., Yan, J., Xu, Y., Quek, K., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1104-z · Cited by 55
Self-citationRos, J., Baraibar, I., Gonzalez, N. S., Rodríguez-Castells, M., Salvà, F., Tabernero, J. M., & Élez, E. (2023) · Cancers · doi:10.3390/cancers15174245 · Cited by 64
“While several mechanisms of resistance have been well characterized in other tumor types, in the case of MSI mCRC there is a lack of well-established biomarkers [61,62].”
BackgroundMariniello, A., Borgeaud, M., WEINER, M. H., Frisone, D., Kim, F., & Addeo, A. (2025) · BioDrugs · doi:10.1007/s40259-024-00700-2 · Cited by 78
“Inactivating mutations of the serine/threonine kinase 11 (STK11), also known as liver kinase B1 (LKB1), have been described as a driver of primary intrinsic resistance to immunotherapy in NSCLC [88, 89].”
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 70
“…activating KRAS mutations and loss-of-function TP53 alterations typically respond well to ICIs 79,93 , although the presence of co-occurring mutations in STK11 / LKB1 or KEAP1 is linked with low levels of PD-L1 expression, minimal immune cell infiltration and resistance to these agents 25,93–95 .”
Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors
Gjoerup, O. V., Brown, C. A., Ross, J. S., Huang, R. S. P., Schrock, A. B., Creeden, J., Fabrizio, D. A., & Tolba, K. A. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00514-4 · Cited by 55
“Mutational inactivation of the tumor suppressors KEAP1 and STK11/ LKB1, individually or in combination, in NSCLC was initially shown to act as a negative predictor of ICPI responses (121,122).”
BackgroundSelf-citationTumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
Barroso‐Sousa, R., Pacifico, J. P. M., Sammons, S. L., & Tolaney, S. M. (2023) · Cancers · doi:10.3390/cancers15153997 · Cited by 58
“by disrupting MHC class I [58,59]; JAK1/2 [59] and STK11 [60] mutations; WNT/b-catenin pathway alterations [61,62]; and PTEN loss [63].”
BackgroundPritchett, M. A., Camidge, D. R., Patel, M., Khatri, J., Boniol, S., Friedman, E. K., Khomani, A., Dalia, S. M., Baker-Neblett, K. L., Plagnol, V., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00299 · Cited by 56
Li, Z., Dang, X., Huang, D., Jin, S., Li, W., Shi, J., Wang, X., Zhang, Y., Song, Z., Zhang, J., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00110-3 · Cited by 49
Self-citationAdvances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang
Ma, J., Yao, Y., Tian, Y., Chen, K., & Liu, B. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00469-5 · Cited by 51
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
Zhou, K., Li, S., Zhao, Y., & Cheng, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127071 · Cited by 56
“A study suggests that KEAP1 mutation in NSCLC is correlated with inferior ICIs response (127), and patients carrying both STK11 and KEAP1 mutations had worse outcomes compared with those harboring one mutation, suggesting an additive effect of these mutations (128, 129).”
BackgroundInfluentialHepatoid adenocarcinoma—Clinicopathological features and molecular characteristics
Li, M., Mei, Y., Wen, J., Jiao, Y.-R., Pan, Q.-R., Kong, X.-X., & Li, J. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216104 · Cited by 56
Remón, J., Hendriks, L. E. L., Cabrera, C., Reguart, N., & Besse, B. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.006 · Cited by 52
“Interestingly, inactivation of STK11 (or its protein product, LKB1) by mutational or non-mutational mechanisms has been associated with an inert or “cold” tumor immune-microenvironment [50].”
BackgroundGurtner, K., Kryzmien, Z., Koi, L., Wang, M., Benes, C. H., Hering, S., Willers, H., Baumann, M. A., & Krause, M. (2019) · International Journal of Cancer · doi:10.1002/ijc.32598 · Cited by 54
Keenan, T. E., Guerriero, J. L., Barroso‐Sousa, R., Li, T., O’Meara, T. A., Giobbie‐Hurder, A., Tayob, N., Hu, J., Severgnini, M., Agudo, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25769-z · Cited by 54
Resistance to immune checkpoint inhibitors and the tumor microenvironment
Kawashima, S., & Togashi, Y. (2022) · Experimental Dermatology · doi:10.1111/exd.14716 · Cited by 55
Boumelha, J., de Castro, A., Bah, N. K., Cha, H., Trécesson, S. D. C., Rana, S., Tomaschko, M., Anastasiou, P., Mugarza, E., Moore, C., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2627 · Cited by 57
Jain, K. K. (2020) · Medical Principles and Practice · doi:10.1159/000511107 · Cited by 55
Gao, Y., Xu, Q., Li, X., Guo, Y. L., Zhang, B., Jin, Y., Zhu, C., Shen, Y., Yang, P., Shi, Y., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04654-7 · Cited by 52
“Unfortunately, only a limited number of patients have demonstrated long-term responses to the therapies based on immune checkpoints [6, 7].”
BackgroundThe role of selected non-coding RNAs in the biology of non-small cell lung cancer
Kiełbowski, K., Ptaszyński, K., Wójcik, J., & Wojtyś, M. E. (2023) · Advances in Medical Sciences · doi:10.1016/j.advms.2023.02.004 · Cited by 49
LKB1 controls inflammatory potential through CRTC2-dependent histone acetylation
Compton, S. E., Kitchen-Goosen, S. M., DeCamp, L. M., Lau, K. H., Mabvakure, B. M., Vos, M., Williams, K. S., Wong, K., Shi, X., Rothbart, S. B., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.04.017 · Cited by 51
Self-citationBhalla, S., Fattah, F. J., Ahn, C. W., Williams, J. N., Macchiaroli, A., Padro, J., Pogue, M., Dowell, J. E., Putnam, W. C., McCracken, N. W., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107291 · Cited by 57
Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
Zhuang, Y., Liu, C. X., Liu, J., & Li, G. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s239398 · Cited by 50
“In the KRAS mutant mouse lung adenocarcinoma model, STK11/LKB1 deletion promoted PD-1/PD-L1 inhibitor resistance.(93)”
BackgroundPseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature
Zhou, L., Zhang, M., Li, R., Xue, J., & Lü, Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03360-1 · Cited by 53
Targeting TANK-binding kinase 1 (TBK1) in cancer
Revach, O., Liu, S., & Jenkins, R. W. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1826929 · Cited by 55
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
Indini, A., Rijavec, E., Ghidini, M., Cortellini, A., & Grossi, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050653 · Cited by 51
“This putative immune sensitizing feature of KRAS mutation can be partly impaired by the concomitant presence of other mutations, as loss or alteration of serine-threonine kinase 11 (STK11)/liver kinase B1 (LKB1), which acts as a genomic driver of primary resistance to immune-checkpoint inhibitors [25,26].”
BackgroundPassaro, A., Attili, I., Rappa, A., Vacirca, D., Ranghiero, A., Fumagalli, C., Guarize, J., Spaggiari, L., de Marinis, F., Barberis, M. C. P., et al. (2021) · Cancers · doi:10.3390/cancers13092172 · Cited by 49
Frigola, J., Navarro, A., Carbonell, C., Callejo, A., Iranzo, P., Cedrés, S., Martínez‐Martí, A., Pardo, N., Gonzalez, N. S., Martinez, D., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12891 · Cited by 53
Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases
Huang, R. S. P., Harries, L., Decker, B. J., Hiemenz, M., Murugesan, K., Creeden, J., Tolba, K. A., Stabile, L. P., Ramkissoon, S. H., Burns, T. F., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac094 · Cited by 52
Self-citationCancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity
Mansouri, S., Heylmann, D., Stiewe, T., Kracht, M., & Savai, R. (2022) · eLife · doi:10.7554/elife.79895 · Cited by 47
Moreo, E., Jarit-Cabanillas, A., Robles‐Vera, I., Uranga, S., Guerrero, C., Gómez, A. B., Mata-Martínez, P., Minute, L., Araujo‐Voces, M., Felgueres, M. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41768-8 · Cited by 48
“However, a considerable proportion of patients with lungtumors(~70%)failtobene fi tfromICIs 7,8 ,leavingthemwithlimited therapeutic options.”
Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
Carvalho, P. D., Machado, A. L., Martins, F., Seruca, R., & Velho, S. (2019) · Cancers · doi:10.3390/cancers11122010 · Cited by 51
“In contrast, the KP group is characterized by dense T-cell infiltration, high expression of PD-L1, and increased response to anti-PD-1 therapy [54,55].”
BackgroundRole of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival
Amanam, I. U., Mambetsariev, I., Gupta, R., Achuthan, S., Wang, Y., Pharaon, R. R., Massarelli, E., Koczywas, M., Reckamp, K. L., & Salgia, R. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.04.18 · Cited by 48
“Most recently STK11/LKB1 and KEAP1/ NFE2L2 were found to be associated with primary resistance and worse outcomes (20,31).”
BackgroundPavan, A., Bragadin, A. B., Calvetti, L., Ferro, A., Zulato, E., Attili, I., Nardo, G., Maso, A. D., Frega, S., Menin, A. G., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-674 · Cited by 49
“First, when analyzing STK11 status, we could technically evaluate point mutations (SNV) and small insertions and deletions, but not large deletions involving the STK11 gene, nor its epigenetic modifications, that can also account for STK11 inactivation (30,32,76).”
Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker
Fountzilas, E., Kurzrock, R., Vo, H. H., & Tsimberidou, A. M. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab067 · Cited by 50
Bao, R., Spranger, S., Hernandez, K. M., Zha, Y., Pytel, P., Luke, J. J., Gajewski, T. F., Volchenboum, S. L., Cohn, S. L., & Desai, A. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002417 · Cited by 49
Metadata
- Authors
- Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., Ali, S. M., Elvin, J. A., Singal, G., Ross, J. S., Fabrizio, D., Szabo, P. M., Chang, H., Sasson, A., Srinivasan, S., Kirov, S., Szustakowski, J., Vitazka, P., Edwards, R., Bufill, J. A., Sharma, N., Ou, S.-H. I., Peled, N., Spigel, D. R., Rizvi, H., Aguilar, E. J., Carter, B. W., Erasmus, J., Halpenny, D. F., Plodkowski, A. J., Long, N. M., Nishino, M., Denning, W. L., Galan-Cobo, A., Hamdi, H., Hirz, T., Tong, P., Wang, J., Rodriguez-Canales, J., Villalobos, P. A., Parra, E. R., Kalhor, N., Sholl, L. M., Sauter, J. L., Jungbluth, A. A., Mino-Kenudson, M., Azimi, R., Elamin, Y. Y., Zhang, J., Leonardi, G. C., Jiang, F., Wong, K.-K., Lee, J. J., Papadimitrakopoulou, V. A., Wistuba, I. I., Miller, V. A., Frampton, G. M., Wolchok, J. D., Shaw, A. T., Jänne, P. A., Stephens, P. J., Rudin, C. M., Geese, W. J., Albacker, L. A., & Heymach, J. V.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Foundation Medicine (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Massachusetts General Hospital (US)
- 3Bristol-Myers Squibb Co., Princeton, New Jersey.
- 7Michiana Hematology Oncology, Mishawaka, Indiana.
- 8Novartis Institute of Biomedical Research, East Hanover, New Jersey.
- University of California, Irvine (US)
- Tel Aviv University (IL)
- Sarah Cannon (US)
- 5Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Brigham and Women's Hospital (US)
- 1Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 17Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- NYU Langone Health (US)
- Corresponding author
- Albacker, Lee A.
- Heymach, John V.
- ORCID
- Skoulidis, Ferdinandos
- Goldberg, Michael E.
- Greenawalt, Danielle M.
- Hellmann, Matthew D.
- Awad, Mark M.
- Gainor, Justin F.
- Schrock, Alexa B.
- Hartmaier, Ryan J.
- Trabucco, Sally E.
- Gay, Laurie
- Ali, Siraj M.
- Elvin, Julia A.
- Ross, Jeffrey S.
- Fabrizio, David
- Sasson, Ariella
- Srinivasan, Sujaya
- Kirov, Stefan
- Szustakowski, Joseph
- Edwards, Robin
- Sharma, Neelesh
- Ou, Sai-Hong I.
- Peled, Nir
- Spigel, David R.
- Rizvi, Hira
- Carter, Brett W.
- Plodkowski, Andrew J.
- Nishino, Mizuki
- Denning, Warren L.
- Hirz, Taghreed
- Tong, Pan
- Wang, Jing
- Parra, Edwin R.
- Kalhor, Neda
- Sholl, Lynette M.
- Sauter, Jennifer L.
- Jungbluth, Achim A.
- Mino-Kenudson, Mari
- Elamin, Yasir Y.
- Zhang, Jianjun
- Leonardi, Giulia C.
- Jiang, Fei
- Wong, Kwok-Kin
- Papadimitrakopoulou, Vassiliki A.
- Wistuba, Ignacio I.
- Miller, Vincent A.
- Frampton, Garrett M.
- Wolchok, Jedd D.
- Shaw, Alice T.
- Rudin, Charles M.
- Geese, William J.
- Albacker, Lee A.
- Heymach, John V.
- Venue
- Cancer Discovery
- Published
- 2018-07-01
- Volume
- 8
- Issue
- 7
- Pages
- 822-835
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6030433
- OpenAlex
- W2804812017
- Cited by
- 1,641
- References
- 56
- Citations by year
- 2026: 182 · 2025: 191 · 2024: 196 · 2023: 211 · 2022: 223 · 2021: 264 · 2020: 239 · 2019: 108 · 2018: 26
- FWCI
- 59.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Association for Cancer Research (AACR) (SU2C-AACR-DT17-15)
- HHS | NIH | National Cancer Institute (NCI) (P30 CA016672, P30 CA008748, P50 CA070907, 1R01 CA205150, 1R01 CA203636)
- Sabin Family Foundation (Sabin Family Foundation Fellowship)
- Khalifa Bin Zayed Al Nahyan Foundation (Khalifa Bin Zayed Al Nahyan Foundation Scholar Award)
- Jane Ford-Petrin Fund (Jane Ford-Petrin Fund)
- Cancer Prevention and Research Institute of Texas (CPRIT) (RP160652)
- V Foundation for Cancer Research (V Foundation) (V Foundation Translational Award)
- The University of Texas MD Anderson Lung Cancer Moonshots Program
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- KRAS-mutant lung adenocarcinoma, anti-PD-1 resistance, PD-L1 expression, tumor mutational burden, nivolumab, immune checkpoint inhibitors, TP53 mutation, non-small cell lung cancer, immunotherapy biomarkers, combination immunotherapy, progression-free survival
- MeSH terms
- Antineoplastic Agents, Immunological, Adenocarcinoma of Lung, Nivolumab, Progression-Free Survival, AMP-Activated Protein Kinase Kinases, Adult, Aged, Aged, 80 and over, Animals, Disease Models, Animal, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Mutation, Prognosis, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Drug Resistance, Neoplasm, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.